Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Metharbital. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metharbital SCHEMBL78867 | 0.83 | ATM (0.60) | LMNAATMSMN1; SMN2ELANEMEN1 | |
| Trimethadione SCHEMBL28882 | 0.77 | LMNA (1.00) | LMNAELANECTSGPRTN3 | |
| Trimethadione SCHEMBL27535502 | 0.75 | LMNA (0.95) | LMNAELANECTSGPRTN3 | |
| Paramethadione SCHEMBL23832172 | 0.75 | LMNA (0.70) | LMNAELANECTSGPRTN3 | |
| Ethadione SCHEMBL13724326 | 0.71 | LMNA (0.70) | LMNAELANECTSGPRTN3 | |
| Trimethadione SCHEMBL13724328 | 0.70 | LMNA (0.83) | LMNAELANECTSGPRTN3 | |
| Metharbital SCHEMBL28086124 | 0.69 | LMNA (0.55) | LMNAATMELANEKMT2A | |
| Paramethadione SCHEMBL34857 | 0.66 | LMNA (0.56) | LMNAATMELANECTSGPRTN3 | |
| Paramethadione SCHEMBL317346 | 0.66 | LMNA (0.56) | LMNAATMELANECTSGPRTN3 | |
| Mephobarbital SCHEMBL1004749 | 0.66 | LMNA (0.86) | LMNAATMELANEMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096924-A1 | Amorphous Composition | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096924-A1 | Amorphous Composition | CACNA1B, CACNA1I, TRPV1 | LMNA 1497/4885ATM 2870/4885SMN1; SMN2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.